These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17164759)

  • 1. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells.
    Ammerpohl O; Trauzold A; Schniewind B; Griep U; Pilarsky C; Grutzmann R; Saeger HD; Janssen O; Sipos B; Kloppel G; Kalthoff H
    Br J Cancer; 2007 Jan; 96(1):73-81. PubMed ID: 17164759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.
    Welsch L; Welsch T; Dovzhanskiy DI; Felix K; Giese NA; Krysko DV; Werner J
    Int J Oncol; 2012 Feb; 40(2):427-35. PubMed ID: 22020984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
    Passacantilli I; Panzeri V; Terracciano F; Delle Fave G; Sette C; Capurso G
    Oncol Rep; 2018 Apr; 39(4):1984-1990. PubMed ID: 29393478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.
    Henderson SE; Ding LY; Mo X; Bekaii-Saab T; Kulp SK; Chen CS; Huang PH
    Neoplasia; 2016 Dec; 18(12):765-774. PubMed ID: 27889645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
    Arnold NB; Arkus N; Gunn J; Korc M
    Clin Cancer Res; 2007 Jan; 13(1):18-26. PubMed ID: 17200334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
    Awasthi N; Yen PL; Schwarz MA; Schwarz RE
    J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
    Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
    J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
    Dovzhanskiy DI; Arnold SM; Hackert T; Oehme I; Witt O; Felix K; Giese N; Werner J
    BMC Cancer; 2012 Jun; 12():226. PubMed ID: 22681698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
    Kawanami T; Takiguchi S; Ikeda N; Funakoshi A
    Oncol Rep; 2012 Mar; 27(3):867-72. PubMed ID: 22200743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication.
    Forster T; Rausch V; Zhang Y; Isayev O; Heilmann K; Schoensiegel F; Liu L; Nessling M; Richter K; Labsch S; Nwaeburu CC; Mattern J; Gladkich J; Giese N; Werner J; Schemmer P; Gross W; Gebhard MM; Gerhauser C; Schaefer M; Herr I
    Oncotarget; 2014 Mar; 5(6):1621-34. PubMed ID: 24742583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of an anticancer activity of combination of interferon-alpha and gemcitabine on pancreatic cancer cells.
    Isayev O; Sokolova DV; Anisimova NY; Spirina TS; Gasimov E
    J Cancer Res Ther; 2024 Jul; 20(5):1494-1498. PubMed ID: 39412913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
    Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
    Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
    Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
    Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.